In-house bioequivalence testing to be acceptable, KFDA says

The government will accept drug maker's in-house bioequivalence testing only, and the acceptable number of the joint bioequivalence testing items will be limited to five, the Korea Food and Drug Administration (KFDA) said on November 15.

According to the newly revised pharmaceutical law that will go into effect February, 2007, pharmaceutical companies will be required to conduct their own bi...